What is the main purpose of this 8-K filing?

The primary purpose of this 8-K filing is to inform investors about Pfizer's agreement to settle patent litigation concerning its drug Lipitor with Ranbaxy Laboratories Ltd. and its affiliates.

What is the significance of settling Lipitor patent litigation?

Settling patent litigation, especially for a major drug like Lipitor, is significant because it provides clarity on future market exclusivity. It helps prevent or delay the entry of generic competition, thus protecting Pfizer's revenue stream from this critical product.

What does 'substantially all their patent litigation worldwide' imply?

This phrase suggests that the agreement is comprehensive and aims to resolve all significant legal disputes concerning Lipitor's patents across all major global markets, thereby offering a broad resolution to potential patent challenges.

Where can I find more details about this settlement?

More details about the settlement can be found in the press release issued by Pfizer Inc. on June 18, 2008, which is attached as Exhibit 99 to this 8-K filing.

PFE 8-K SEC Disclosure — Jun 18, 2008

Summary

Pfizer Inc. (PFE) filed an 8-K on June 18, 2008, to announce a significant development regarding its blockbuster cholesterol-lowering drug, Lipitor. The company reported reaching an agreement with Ranbaxy Laboratories Ltd. and its affiliates to settle substantially all worldwide patent litigation concerning Lipitor. This settlement is a crucial event for investors as it addresses potential patent challenges that could have led to generic competition and revenue erosion for one of Pfizer's key products.

Key Highlights

1Pfizer Inc. has reached a settlement agreement with Ranbaxy Laboratories Ltd. and its affiliates.
2The settlement pertains to substantially all worldwide patent litigation involving the drug Lipitor.
3This agreement aims to resolve ongoing legal disputes related to Lipitor's patents.
4The event date reported is June 17, 2008, with the filing on June 18, 2008.
5The press release detailing this agreement is included as Exhibit 99 to the 8-K filing.

PFIZER INC 8-K Report, Corporate Update (Jun 18, 2008)

Summary

Key Highlights

Frequently Asked Questions